We have therefore now evaluated the clinical background of patients with NSCLC positive for EGFR or HER2 exon-20 mutations as well as their response to treatment including that with the immune-checkpoint inhibitor nivolumab. This evidence concerns the gene EGFR and non-small cell lung carcinoma.